Frédéric Triebel

Dr. Frédéric Triebel is a French immunologist and cancer researcher who has spent their career investigating ways to harness the immune system to treat cancer. Frédéric is currently the Chief Scientific Officer and Chief Medical Officer at Immutep, a company they co-founded in 2004.

Prior to their current role, Dr. Triebel was a Professor of Immunology at Universite Paris Sud from 1990-2004, and Head of Cellular Immunology at Institut Gustave Roussy from 1986-2002. At Institut Gustave Roussy, they conducted Phase I/II clinical trials and immunomonitoring in cancer patients receiving immunotherapy, cancer vaccines, or gene therapy. Their research activity focused on tumour immunology.

Throughout their career, Dr. Triebel has been driven by the belief that harnessing the power of the immune system can provide more effective cancer treatments with fewer side effects than traditional chemotherapy and radiation therapy. This belief has led him to pioneer several groundbreaking immunotherapy treatments that are helping cancer patients around the world live longer, healthier lives.

Their manager is Marc Voigt, CEO. Frédéric Triebel works with Claudia Jacoby - Director of Manufacturing, Christian Mueller - VP, Strategic Development, and Deanne Miller - COO, General Counsel & Company Secretary.